Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
NCT04854746
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
Norovirus Infections
Interventions
BIOLOGICAL:
VXA-GI.1.NN
BIOLOGICAL:
Placebo Tablet
Sponsor
Vaxart